Prime Medicine Earnings Call Transcripts
Fiscal Year 2026
-
Two in vivo programs are advancing to the clinic with data expected in 2027, while a revived ex vivo program benefits from regulatory flexibility and reduced costs. Prime Editing's DNA-level correction offers broad applicability, strong safety, and competitive advantages in genetic diseases.
-
The company is advancing its first in vivo liver-directed clinical programs for Wilson disease and alpha-1 antitrypsin deficiency, with regulatory filings expected soon and initial clinical data anticipated in 2027. Strategic partnerships, a strong IP position, and a cash runway into 2027 support a focused pipeline and ongoing business development.
-
Prime Editing technology enables precise, safe genome editing with broad disease potential and strong IP protection. Lead programs in Wilson disease and alpha-1 antitrypsin deficiency are advancing toward clinical trials, supported by a $227M cash position and strategic partnerships.
Fiscal Year 2025
-
Prime editing is positioned as a safer, more versatile gene editing technology, with a strategic focus on high-value programs like Wilson disease and alpha-1 antitrypsin deficiency. Lead programs are advancing toward clinical trials, with data expected in 2027.
-
Prime Editing is positioned as a highly versatile and safe gene editing platform, advancing programs in Wilson's disease, AATD, and cystic fibrosis with promising preclinical data and differentiated delivery technology. Key regulatory filings and clinical milestones are expected over the next year.
-
The event detailed a strategy to address Wilson disease using prime editing, highlighting strong preclinical efficacy, a large addressable market, and a modular platform for rapid expansion. IND/CTA filing is planned for 2026, with initial human data expected in 2027.
-
Panelists at a leading genome editing conference discussed the coexistence of editing technologies, the importance of delivery optimization, and the shift toward commercially viable, one-time therapies. Advances in LNP and AAV delivery, platform synergies, and a focus on cost and access are shaping the next wave of clinical programs.
-
Prime Editing technology enables precise, safe, and versatile gene editing, with a current focus on liver diseases such as Wilson's and alpha-1 antitrypsin deficiency. Key programs are set to enter the clinic in 2025, with data expected in 2027, supported by a strong cash position and strategic collaborations.
-
Strategic focus is on high-potential liver and cystic fibrosis programs, leveraging Prime Editing’s precision and safety advantages. INDs for Wilson’s disease and Alpha-1 antitrypsin deficiency are targeted for 2026, with phase 1 data expected in 2027. Financial runway extends into 2027, supported by cost reductions and partnerships.
-
Leadership transition led to a focused pipeline of three core programs and a major BMS collaboration. INDs for Wilson's and AATD are expected in 2025, with clinical data in 2027. Strong preclinical data, a robust financial position, and ongoing BD efforts support long-term growth.
-
Prime editing is highlighted as a versatile, safer gene editing platform with strong preclinical and initial clinical data, especially in CGD and Wilson's disease. The pipeline is advancing toward key IND filings and clinical milestones, supported by a strengthened cash position and ongoing business development discussions.
-
Prime editing programs are advancing, with first clinical data in CGD expected this year and rapid progress in Wilson's disease and cystic fibrosis by 2026. The pipeline was streamlined for value, and a major partnership with Bristol supports CAR-T development. No off-target editing detected in clinical programs.
-
Prime Editing platform advances toward clinical milestones in CGD, Wilson's disease, and cystic fibrosis, supported by strong preclinical data, strategic partnerships, and a modular approach enabling rapid pipeline expansion. Initial clinical data for CGD is expected in 2024.
Fiscal Year 2024
-
Prime Editing technology enables versatile and precise genome edits, with a strategic focus on high-value programs like CGD and Wilson's disease. A major BMS partnership validates the platform and supports funding, while clinical and preclinical milestones are expected in the next 12–18 months.
-
Prime editing technology enables precise, safe correction of genetic mutations, with lead programs in CGD, Wilson's disease, and cystic fibrosis. Clinical data for CGD is expected in 2025, and strategic reprioritization has focused resources on high-potential indications.
-
Pipeline narrowed to six high-value programs, with CGD and Wilson's disease as key focuses. CGD trials aim for pivotal data by 2025, while Wilson's disease IND is targeted for 2026, leveraging a universal LNP platform. The BMS partnership brings significant funding and validation.
-
Prime editing technology is advancing with a strategic BMS collaboration, pipeline reprioritization, and a global CGD clinical trial. Financial runway is extended, and new data for Wilson’s disease and cystic fibrosis are anticipated. Market differentiation and investor interest remain strong.
-
Prime Editing technology enables precise, efficient gene correction with a strong safety profile and modular delivery systems. The lead program for CGD is in phase I/II, with data expected next year and a robust pipeline targeting liver, lung, and ocular diseases. Partnerships and business development are central to funding and advancing the pipeline.
-
Prime Editing has rapidly advanced to clinical stage, with a robust IP portfolio and a focused pipeline. The first IND targets CGD, aiming for a one-time cure, with initial human data expected in 2025. Financially, the company is well-positioned through 2025 and is pursuing partnerships.
-
Prime editing technology enables precise, safe gene correction with broad disease potential. Lead CGD program is advancing to clinical trials, with international expansion and a focus on safety and efficacy endpoints. Modular LNP platform and early pipeline data in eye, CNS, and muscle diseases highlight future growth.